## UNH: UnitedHealth Group Incorporated - XLV: Healthcare

### Executive Summary

VALUE thesis: PEG 1.26 indicates fundamental undervaluation. Quality metrics strong (ROE 18%).

- **Horizon:** 20-60 days (position)
- **Risk Profile:** Lower - fundamental undervaluation
- **Stop Type:** Fixed 2xATR ($320.75)
- **If Wrong:** Exit if fundamentals deteriorate or stop hit
- **Invalidation:** PEG > 1.5 or earnings miss

### News

- **Articles:** 10
- **Sentiment:** Bullish (Bullish: 3, Bearish: 1)

**1. UnitedHealth Group Stock (UNH) Rallies on Analyst Upgrades, Latin America Exit and New ETF: December 3, 2025 Outlook**
- Source: ts2.tech | 20251203T183741 | Bullish | Relevance: 100%
- UnitedHealth Group (UNH) stock rallied on December 3, 2025, driven by analyst upgrades, the company's strategic exit from Latin America, and the launch of a new single-stock ETF. Despite a turbulent year marked by a cyberattack and fraud probe, the stock saw a significant bounce due to a $1.6 billion investment from Warren Buffett and renewed bullish sentiment from Wall Street. The article deep dives into the catalysts, Q3 2025 earnings, strategic recalibrations for Medicare Advantage, and ongoing legal and regulatory challenges facing UNH.

**2. Why UnitedHealth (UNH) Stock Is Up Today**
- Source: Finviz | 20251203T152500 | Bullish | Relevance: 100%
- UnitedHealth (UNH) shares rose 4.5% due to positive analyst actions and strategic company updates, including lifted price targets by Wolfe Research, Bernstein, and RBC Capital. The optimism stems from the belief that UnitedHealth can improve profit margins in its insurance division. This move follows a previous gain tied to hopes for an interest rate cut, though the stock is still significantly down year-to-date.

**3. Wells Fargo Analyst has a Positive Outlook on UnitedHealth Group (UNH)**
- Source: Finviz | 20251202T010200 | Somewhat-Bullish | Relevance: 100%
- Wells Fargo analyst Stephen Baxter assigned a Buy rating to UnitedHealth Group (UNH) with a price target of $400. This comes amidst ongoing discussions between UnitedHealthcare and TriHealth regarding compensation, which could lead to TriHealth providers leaving UNH's network and affecting up to 80,000 patients. UnitedHealth Group is noted as a strong dividend stock, providing health benefit plans and services.

**4. UnitedHealth Sells Last South American Asset For $1 Billion: Report**
- Source: Stocktwits | 20251201T105300 | Bearish | Relevance: 100%
- UnitedHealth Group (UNH) has agreed to sell its final South American asset, Banmedica, to Patria Investments for approximately $1 billion, concluding its planned exit from Latin America that began in 2022. The company recorded an $8.3 billion loss in 2024 related to these divestments. This strategic move aims to stabilize the company amidst rising medical costs, a federal investigation, and management changes.

**5. Up 37% Since August, Is It Safe to Buy UnitedHealth Group Stock Again?**
- Source: The Motley Fool | 20251203T170600 | Neutral | Relevance: 100%
- UnitedHealth Group's stock has rallied 37% since August, largely due to an investment by Berkshire Hathaway, despite facing headwinds like rising costs and a DOJ investigation. The company has boosted its guidance and its valuation remains relatively modest, suggesting it could be a long-term investment for patient investors. However, significant challenges and uncertainties regarding its billing practices and cost controls persist.

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **MIXED** |
| Buys | 23 ($0.00M) |
| Sells | 0 ($0.00M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 39.4% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 5 / 5 |

**Top Holders:**
- Vanguard Group Inc: 10.0% (-0.3%)
- Blackrock Inc.: 8.2% (-1.4%)
- State Street Corpora: 4.9% (-1.8%)
- JPMORGAN CHASE & CO: 4.1% (+85.6%)
- Geode Capital Manage: 2.4% (+2.2%)

### Key Risks

1. Long-term trend broken: trading 6.6% below SMA200.
2. Market regime shift could impact momentum names disproportionately.
3. Sector rotation risk if leadership changes from current market theme.

### Catalysts

- AI/machine learning initiatives could drive multiple expansion if executed.
- Momentum building: MRS_20 improving +2.4% over 5 days suggests accumulation.

### Fundamentals

PEG ratio 1.26 suggests fair value with growth premium. Forward P/E 19.1x stretched relative to 9% growth. Balance sheet: $5.1B free cash flow. Institutional flow bullish (5 buying vs 5 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $300.6B |
| Beta | 0.43 |
| 52W Range | $234.60 - $606.36 |
| Short Interest | 1.6% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 1.26 |
| Forward P/E | 19.1 |
| Current P/E | 20.8 |
| YoY Growth | 8.8% |
| EPS Direction | STABLE |

### Technicals

MRS_20 strengthening from 0.5% to 2.9% (+2.4% in 5 days), confirming momentum buildup. Below STRENGTH zone by 1.1pp (needs >4.0% for momentum thesis). MRS_5 at 2.6% confirms short-term momentum alignment. AM_20 at 4.8% shows strong absolute momentum above own 20MA. Outperforming sector by 3.1pp, stock-specific strength. Below SMA200 (0.93x), long-term trend not supportive. MACD histogram positive (2.38), confirming momentum. RSI neutral at 57. OFD pattern: +MTN (Rally).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | 2.86% (CS: 76) | Neutral |
| RSI_14 | 56.6 | Neutral |
| MACD Histogram | 2.38 | Bullish |
| vs SMA20 | 1.048x | Above |
| vs SMA50 | 0.991x | Below |
| vs SMA200 | 0.934x | Below |

### Decision

- **Verdict:** AVOID
- **Thesis:** VALUE

### Trade Setup

- **Entry:** $339.71
- **Stop Loss:** $320.75 (5.6% risk)
- **Target:** $377.63 (R:R method)
- **Risk/Reward:** 2.00:1
- **Target Reasoning:** VALUE thesis targets 2.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 50
- **Position Value:** $16,985.50
- **Portfolio %:** 16.99%
- **Risk Dollars:** $950.00
- **Risk Per Trade:** 0.95%
- **Modifiers:** L1 95% | L2 100% | Combined 0.95x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 0.95x |
| L2 Sector | NEUTRAL (Zone E) | 1.00x |

*NORMAL regime with moderately constructive conditions. Fed dovish pivot expectations from weak jobs data and declining VIX suggest improving risk appetite, though narrow breadth at 51% indicates selective participation. Focus on quality sectors benefiting from rate cut expectations.*

### Earnings

**Next:** 2026-01-15 (Est: $2.10)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $2.81 | $2.92 | +4.0% |
| 2025Q2 | $4.45 | $4.08 | -8.2% |
| 2025Q1 | $7.29 | $7.20 | -1.3% |
| 2024Q4 | $6.74 | $6.81 | +1.1% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_20*